Article info

IFN-γ- and IL-17-producing CD8+ T (Tc17-1) cells in combination with poly-ICLC and peptide vaccine exhibit antiglioma activity

Authors

  • Takayuki Ohkuri Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USABrain Tumor Program, University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, Pittsburgh, PA, USA PubMed articlesGoogle scholar articles
  • Akemi Kosaka Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USABrain Tumor Program, University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, Pittsburgh, PA, USA PubMed articlesGoogle scholar articles
  • Maki Ikeura Brain Tumor Program, University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, Pittsburgh, PA, USA PubMed articlesGoogle scholar articles
  • Andres M Salazar Oncovir, Inc, Washington, District of Columbia, USA PubMed articlesGoogle scholar articles
  • Hideho Okada Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USABrain Tumor Program, University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, Pittsburgh, PA, USADepartment of Neurological Surgery, University of California San Francisco, San Francisco, California, USAParker Institute for Cancer Immunotherapy, San Francisco, CA, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Hideho Okada; hideho.okada{at}ucsf.edu
View Full Text

Citation

Ohkuri T, Kosaka A, Ikeura M, et al
IFN-γ- and IL-17-producing CD8+ T (Tc17-1) cells in combination with poly-ICLC and peptide vaccine exhibit antiglioma activity

Publication history

  • Accepted May 16, 2021
  • First published June 30, 2021.
Online issue publication 
June 30, 2021
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.